Mitsubishi UFJ Asset Management Co. Ltd. Buys New Position in Boston Scientific Corporation $BSX

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, HoldingsChannel reports. The fund purchased 3,617,472 shares of the medical equipment provider’s stock, valued at approximately $154,394,000.

Other hedge funds also recently made changes to their positions in the company. Norges Bank bought a new stake in shares of Boston Scientific in the fourth quarter worth $2,199,395,000. Bank of New York Mellon Corp bought a new position in Boston Scientific in the second quarter valued at $339,031,000. Assenagon Asset Management S.A. increased its stake in Boston Scientific by 133.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock valued at $631,135,000 after buying an additional 5,751,760 shares during the last quarter. Janus Henderson Group PLC lifted its position in Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after buying an additional 3,907,981 shares in the last quarter. Finally, Maverick Capital Ltd. acquired a new position in shares of Boston Scientific during the 4th quarter worth about $280,735,000. 89.07% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Cheryl Pegus acquired 1,770 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders acquired 202,122 shares of company stock worth $9,813,931. Company insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $51.46 on Tuesday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The business’s 50 day moving average price is $46.12 and its two-hundred day moving average price is $58.81. The company has a market cap of $74.58 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm posted $0.75 earnings per share. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has approved a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on BSX shares. Stifel Nicolaus set a $60.00 target price on Boston Scientific in a research report on Wednesday, July 29th. Barclays decreased their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. Royal Bank Of Canada lowered their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. UBS Group dropped their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Piper Sandler reissued an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.